Trial Profile

Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Binimetinib (Primary) ; Encorafenib (Primary)
Indications Biliary cancer; Breast cancer; Colorectal cancer; Malignant melanoma; Pancreatic cancer; Solid tumours; Uterine cancer
Focus Therapeutic Use
Acronyms BEAVER
Sponsors Pfizer

Most Recent Events

03 Feb 2025 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
03 Feb 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.
04 Jun 2024 Results (n=21) assessing efficacy and exploratory objectives of binimetinib and encorafenib (B+E) in patients (pts) with non-V600E BRAF mts advanced Solid Tumors presented at the 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com